Vandetanib for the treatment of medullary thyroid cancer

Clinical Cancer Research

Volumn 19, Issue 3, 2013, Pages 524-529

  Chau, Nicole G ^a   Haddad, Robert I ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CABOZANTINIB; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; LENVATINIB; MOTESANIB; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; VANDETANIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; FISTULA; GENE; HAIR COLOR; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INOPERABLE CANCER; LOW DRUG DOSE; METASTASIS; ONCOGENE RAS; OVERALL SURVIVAL; PAIN; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RECEPTOR BLOCKING; RECOMMENDED DRUG DOSE; RET GENE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMATIC MUTATION; STOMATITIS; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TORSADE DES POINTES; TREATMENT OUTCOME; WATCHFUL WAITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84873325712     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2353     Document Type: Article

References (25)

1. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008;93:682-7.
2. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-30.
3. de Souza JA, Busaidy N, Zimrin A, Seiwert TY, Vilaflor VM, Poluru KM, et al. Phase II trial of sunitinib in medullary thyroid cancer. J Clin Oncol (Meeting Abstracts) 2010;28:5504.
4. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-801.
5. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13.
6. Schlumberger M, Jarzab B, Cabanillas ME, Robinson BG, Pacini F, Ball DW, et al. A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). J Clin Oncol (Meeting Abstracts) 2012;30:5591.
7. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29: 2660-6.
8. Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28: 767-72.
9. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55.
10. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-90.
11. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391-7.
12. Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1:1002-9.
13. Zhang L, Li S, Zhang Y, Zhan J, Zou BY, Smith R, et al. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther 2011;33:315-27.
14. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2664-71.
15. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind Phase III trial. J Clin Oncol 2012;30:134-41.
16. Langmuir PB, Yver A. Vandetanib for the treatment of thyroid cancer. Clin Pharmacol Ther 2012;91:71-80.
17. Haddad RI, Costello R. Medullary thyroid cancer: advances in treatment and management of common adverse events associated with therapy. Commun Oncol 2012;9:188-97.
18. Schoffski P, Ellisei R, Miuller S, Brose MS, Shah MH, Licitra L, et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL-184) in medullary thyroid carcinoma patients with documented RECIST progression at baseline. J Clin Oncol (Meeting Abstracts) 2012;30:5508.
19. Verbeek HH, Alves MM, de Groot JW, Osinga J, Plukker JT, Links TP, et al. The effects offour different tyrosine kinase inhibitorson medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 2011;96: E991-5.
20. Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004;23:6056-63.
21. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-34.
22. Moura MM, Cavaco BM, Pinto AE, Leite V. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 2011;96:E863-8.
23. Morgillo F, Martinelli E, Troiani T, Orditura M, De Vita F, Ciardiello F. Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PLoS One 2011;6:e28841.
24. Vitagliano D, De Falco V, Tamburrino A, Coluzzi S, Troncone G, Chiappetta G, et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer 2011;18:1-11.
25. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008;18:317-23.